A comparison of incidence rates and disparities in cardiovascular risk factors among survivors of childhood cancers compared to siblings and the general public was presented at 2021 ASCO Annual Meeting.
The model appears to predict minimal residual disease status.
Statistically significant benefit was observed with extended letrozole therapy in patients with HR+ breast cancer identified as low-risk, but not in high-risk patients.
Quality of life outcomes were superior with video-assisted thoracoscopic surgery.
Survival results were similar with stereotactic ablative radiotherapy and surgery.
Researchers present results of a clinical trial that evaluated the impact of an LHW intervention on care use and behaviors among patients with advanced cancer and at the end of life during the 2021 ASCO Annual Meeting.
Researchers are running a phase 4 feasibility trial to determine the safety and effectiveness of at-home blinatumomab treatment in patients with MRD-positive B cell precursor ALL.
Researchers are running a phase 4 feasibility trial to determine the safety and effectiveness of at-home blinatumomab treatment in patients with MRD-positive B cell precursor ALL.
Researchers are conducting a randomized phase 3 trial evaluating the safety and efficacy of venetoclax with azacitidine among patients with previously untreated, higher-risk MDS.
The 70-gene signature can identify patients with an ultralow risk of distant recurrence, which can be used to de-escalate treatment and reduce side effects.
